How many institutional investors hold DNTH?

3 tracked institutional investors disclosed a position in DNTH (DIANTHUS THERAPEUTICS INC) in their most recent 13F filing.

Who is the largest institutional holder of DNTH?

Ken Griffin, Citadel Advisors, holds the largest disclosed position in DNTH, valued at $138M.

Where does this DNTH ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

DNTH — DIANTHUS THERAPEUTICS INC

Name: DIANTHUS THERAPEUTICS INC (DNTH) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About DIANTHUS THERAPEUTICS INC (DNTH)

DIANTHUS THERAPEUTICS INC (DNTH) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $138M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in DNTH

100

/100

Strong Institutional Accumulation

Added / Increased2

Reduced0

Exited0

BearishBullish

Crowded Trade Score™

How many top investors track DNTH

/100

Emerging Interest

3investors

A small number of top investors own this.

UndiscoveredCrowded

151015+

DNTH Ownership Composition

How DIANTHUS THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type

Other

75% of tracked value

Institutions

tracked investors

Total Reported

$214.4M

combined 13F value

Other74.8%
Hedge Funds25.2%

Other(2)

74.8%

Hedge Funds(1)

25.2%

Tracked investors reporting DNTH

Investor	Firm	Shares	Market value	% of portfolio	As of
Ken Griffin	Citadel Advisors	1.6M	$138.4M	0.02%	Mar 31, 2026
Steve Cohen	Point72 Asset Management	643.6K	$54M	0.07%	Mar 31, 2026
Izzy Englander	Millennium Management	262K	$22M	0.01%	Mar 31, 2026

Ken GriffinMar 31, 2026
Citadel Advisors
Shares
1.6M
Value
$138.4M
% Portfolio
0.02%
Steve CohenMar 31, 2026
Point72 Asset Management
Shares
643.6K
Value
$54M
% Portfolio
0.07%
Izzy EnglanderMar 31, 2026
Millennium Management
Shares
262K
Value
$22M
% Portfolio
0.01%

Recent activity

Investor	Action	Δ %	Current value	Filing date
Steve Cohen	New	—	$48.1M	Feb 17, 2026
Steve Cohen	New	—	$54M	May 15, 2026

Steve Cohen
New
$48.1MFeb 17, 2026
Steve Cohen
New
$54MMay 15, 2026

Frequently asked questions

How many institutional investors hold DNTH?: 3 tracked institutional investors disclosed a position in DNTH (DIANTHUS THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of DNTH?: Ken Griffin, Citadel Advisors, holds the largest disclosed position in DNTH, valued at $138M.
Did institutional ownership of DNTH increase or decrease?: Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 fully exited DNTH.
Where does this DNTH ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.